{
    "nct_id": "NCT04649359",
    "official_title": "MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY",
    "inclusion_criteria": "* Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)\n* Measurable disease, as defined by at least 1 of the following:\n\n  1. Serum M-protein >0.5 g/dL by SPEP\n  2. Urinary M-protein excretion >200 mg/24 hours by UPEP\n  3. Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio\n* Refractory to at least one IMiD\n* Refractory to at least one PI\n* Refractory to at least one anti-CD38 antibody\n* Relapsed/refractory to last anti-myeloma regimen\n* Cohort A: has not received prior BCMA-directed therapy\n* Cohort B: has received prior BCMA-directed therapy (ADC or CAR T cells)\n* ECOG performance status ≤2\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1\n* Not pregnant and willing to use contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Smoldering multiple myeloma\n* Active Plasma cell leukemia\n* Amyloidosis\n* POEMS syndrome\n* Stem cell transplant within 12 weeks prior to enrollment\n* Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.\n* Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)",
    "miscellaneous_criteria": ""
}